GNXCX | RSLBX | GNXCX / RSLBX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 7 years | 22 years | - |
Gain YTD | -0.451 | 5.379 | -8% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 250 | 1,000% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 13.8M | 76.8B | 0% |
Annual Yield % from dividends | 0.00 | 0.15 | - |
Returns for 1 year | 11.75 | 18.86 | 62% |
Returns for 3 years | -35.65 | -25.32 | 141% |
Returns for 5 years | 0.55 | 17.84 | 3% |
Returns for 10 years | N/A | 28.30 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
RYBHX | 57.32 | -0.13 | -0.23% |
Rydex S&P MidCap 400 Pure Growth H | |||
PGILX | 36.81 | -0.15 | -0.41% |
Putnam Focused Equity Y | |||
MLNAX | 22.90 | -0.11 | -0.48% |
Morgan Stanley Instl Glbl Concntr A | |||
VSEQX | 39.64 | -0.23 | -0.58% |
Vanguard Strategic Equity Inv | |||
PHLCX | 19.48 | -0.15 | -0.76% |
PGIM Jennison Health Sciences C |